GlycoLocate™:
A groundbreaking patent pending platform for early cancer detection.
AOA Dx is pioneering the field of lipidomics
Lipids are an emerging class of biomarkers with strong potential for early cancer detection. These molecules play essential roles in cell signaling, proliferation, and metabolism, and become “reprogrammed” during tumor development. In cancer, lipid profiles shift in characteristic ways that distinguish them from non-cancer cells. Enabled by advances in mass spectrometry and machine learning, lipidomics allows for high-throughput, sensitive detection of these changes. When combined with proteomic and clinical data in a multi-omic approach, lipids offer a powerful path to diagnose cancer early and more accurately.
The GlycoLocate™ Platform is the future
The GlycoLocate™ platform will be the first of its kind to use multi-omics and advanced computational biology algorithms to diagnose early-stage cancers by using a non-invasive blood test.
Early cancer detection,
re-imagined
Our AI-enabled GlycoLocate™ platform will be the first and only to harness the power of lipidomics, combined with other complementary biomarkers, to diagnose cancer earlier, enabling more patients to get access to life-saving treatments sooner. The GlycoLocate™ platform may differentiate between cancers down to their tissue of origin in both symptomatic and non-symptomatic patients. This superior breakthrough technology removes the typical barriers of cost, invasiveness, accessibility, and effectiveness seen with current early detection technologies.
Orthogonal multi-omic biomarkers are the next frontier in early cancer detection
To date, genomics and proteomics have been widely used in precision medicine. AOA Dx is advancing the next generation of diagnostic tools by integrating lipidomics, an emerging field that captures cancer-driven changes in lipid metabolism, alongside proteomics and clinical data. Our AI-powered multi-omic platform enables earlier and more accurate diagnosis by uncovering disease-specific biomarker signatures that appear in the earliest stages of cancer. While our initial focus is ovarian cancer, the platform has potential applications across a range of indications, including breast, lung, melanoma, and neuroblastoma. Through our proprietary GlycoLocate™ platform, we are redefining how cancer is diagnosed at its earliest and most treatable stages.
Ovarian cancer is just the start for AOA Dx and the GlycoLocate™ platform
Developing the platform in collaboration with leading world experts and scientists in conjunction with state-of-the-art data science, we believe we can change the paradigm of early diagnosis of many of the world’s deadliest cancers.
The GylcoLocate™ platform is changing the world of cancer detection to diagnose patients earlier and keep them with their loved ones longer. Find out how AKRIVIS GD™ is transforming women’s health through early ovarian cancer detection
Sources
Nejatie, A., Yee, S. S., Jeter, A. & Saragovi, H. U. The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides. Front Oncol 13, 1261090 (2023). https://doi.org:10.3389/fonc.2023.1261090
Yu, R. K., Tsai, Y. T., Ariga, T. & Yanagisawa, M. Structures, biosynthesis, and functions of gangliosides–an overview. J Oleo Sci60, 537-544 (2011). https://doi.org:10.5650/jos.60.537
Galan, A. et al. GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer.Front Oncol 13, 1134763 (2023). https://doi.org:10.3389/fonc.2023.1134763
Groux-Degroote, S., Rodriguez-Walker, M., Dewald, J. H., Daniotti, J. L. & Delannoy, P. Gangliosides in Cancer Cell Signaling.Prog Mol Biol Transl Sci 156, 197-227 (2018). https://doi.org:10.1016/bs.pmbts.2017.10.003
Caldwell, S. et al. Mechanisms of ganglioside inhibition of APC function. J Immunol 171, 1676-1683 (2003). https://doi.org:10.4049/jimmunol.171.4.1676
Tong, W., Maira, M., Gagnon, M. & Saragovi, H. U. Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. PLoS One 10, e0134255 (2015). https://doi.org:10.1371/journal.pone.0134255
Chen, Y. X. et al. Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen. Oncology reports 29, 343-348 (2013). https://doi.org:10.3892/or.2012.2092
Shibuya, H. et al. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.Cancer Sci 103, 1656-1664 (2012). https://doi.org:10.1111/j.1349-7006.2012.02344.x
Webb, T. J. et al. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res72, 3744-3752 (2012). https://doi.org:10.1158/0008-5472.CAN-11-2695
Orsi, G. et al. GD2 expression in breast cancer. Oncotarget 8, 31592-31600 (2017). https://doi.org:10.18632/oncotarget.16363
Liang, Y. J. et al. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget 8, 47454-47473 (2017). https://doi.org:10.18632/oncotarget.17665
Yoshida, S. et al. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 61, 4244-4252 (2001).
Hamamura, K. et al. Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem 286, 18526-18537 (2011). https://doi.org:10.1074/jbc.M110.164798
Ladisch, S. et al. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39, 73-76 (1987). https://doi.org:10.1002/ijc.2910390113
Balis, F. M. et al. The ganglioside G(D2) as a circulating tumor biomarker for neuroblastoma. Pediatr Blood Cancer 67, e28031 (2020). https://doi.org:10.1002/pbc.28031
Schulz, G. et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44, 5914-5920 (1984).